



TTK Healthcare LIMITED

TTKHC:SEC:SL:189:25

August 04, 2025

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Outcome of the Board Meeting - Disclosure under Regulation 30 of SEBI (LODR)
Regulations, 2015**

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the First Quarter ended June 30, 2025, duly reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held today.

The Board Meeting commenced at 12 noon and concluded at 12.50 p.m.

Kindly take the above information / documents on record.

Thanking you

Yours faithfully

For TTK Healthcare Limited

(GOWRY A JAISHANKAR)
DGM - Legal & Company Secretary

Encl.: a/a



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

Sl. No.	Particulars	For the Quarter ended			(Rs. in lakhs)
		(30/06/2025)	(31/03/2025)	(30/06/2024)	For the Year ended
		Unaudited	Audited	Unaudited	(31/03/2025)
					Audited
I.	Revenue from Operations	22,642.98	19,035.96	20,790.21	80,149.34
II.	Other Income	1,793.56	1,868.87	1,702.64	7,125.49
III.	Total Income (I + II)	24,436.54	20,904.83	22,492.85	87,274.83
IV.	Expenses:				
	(a) Cost of materials consumed	4,956.72	4,957.80	4,944.61	19,533.81
	(b) Purchase of Stock-in-trade	4,702.74	4,811.10	4,559.84	18,694.85
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	522.40	(1,018.40)	(151.17)	(1,337.02)
	(d) Employee benefits expense	4,133.08	3,640.15	3,836.08	15,090.96
	(e) Finance Costs	76.96	90.47	85.79	332.42
	(f) Depreciation and Amortization Expense	218.81	216.69	205.14	833.37
	(g) Other Expenses	8,060.48	5,445.03	6,910.18	24,683.92
	Total Expenses (IV)	22,671.19	18,142.84	20,390.47	77,832.31
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	1,765.35	2,761.99	2,102.38	9,442.52
VI.	Exceptional Items (Ref. Note 3 below)	-	(586.39)	1,977.05	1,390.66
VII.	Profit / (Loss) before Tax (V - VI)	1,765.35	2,175.60	4,079.43	10,833.18
VIII.	Tax Expense:				
	(1) Current Tax	465.00	540.00	935.00	2,655.00
	(2) Deferred Tax	0.41	20.77	(13.08)	12.49
IX.	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	1,299.94	1,614.83	3,157.51	8,165.69
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-
XI.	Tax Expense from Discontinued Operations	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-
XIII.	Profit / (Loss) for the period (IX + XII)	1,299.94	1,614.83	3,157.51	8,165.69
XIV.	Other Comprehensive Income:				
	(A) (i) Items that will not be reclassified subsequently to profit or loss	59.45	(658.49)	203.42	(402.94)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(2.26)	95.93	(13.95)	63.21
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]	1,357.13	1,052.27	3,346.98	7,825.96
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet (excluding Revaluation Reserve)				1,04,650.36



Sl. No.	Particulars	For the Quarter ended			For the Year ended
		(30/06/2025)	(31/03/2025)	(30/06/2024)	(31/03/2025)
		Unaudited	Audited	Unaudited	Audited
XVI.	Earnings per Equity Share (For Continuing Operations):				
(1)	Basic (in Rs.)	9.20	11.43	22.35	57.79
(2)	Diluted (in Rs.)	9.20	11.43	22.35	57.79
XVII.	Earnings per Equity Share (For Discontinued Operations):				
(1)	Basic (in Rs.)	-	-	-	-
(2)	Diluted (in Rs.)	-	-	-	-
XVIII.	Earnings per Equity Share (For Continuing and Discontinued Operations):				
(1)	Basic (in Rs.)	9.20	11.43	22.35	57.79
(2)	Diluted (in Rs.)	9.20	11.43	22.35	57.79

Notes:

- (1) The above financial results for the First Quarter ended June 30, 2025 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 04, 2025 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3)
 - (a) During the first quarter of the previous year, the Company had sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
 - (b) During the fourth quarter of the previous year, the Company had written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers.
- (4) The figures for the Quarter ended March 31, 2025 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to Limited Review.
- (5) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (6) The full financial results for the First Quarter ended June 30, 2025 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED

Place : Chennai
Date : August 04, 2025

T T RAGHUNATHAN
Executive Chairman



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER ENDED JUNE 30, 2025

(Rs. in lakhs)					
Sl. No.	Particulars	For the Quarter ended			For the Year ended
		(30/06/2025)	(31/03/2025)	(30/06/2024)	(31/03/2025)
		Unaudited	Audited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)				
	(a) Animal Welfare	3,188.39	3,060.10	3,111.19	12,637.05
	(b) Consumer Products	7,563.04	5,290.85	7,314.28	24,492.52
	(c) Medical Devices	2,886.80	2,259.66	2,457.87	9,014.53
	(d) Protective Devices	5,271.24	4,759.60	4,628.83	20,663.87
	(e) Foods	3,724.33	3,653.95	3,270.01	13,305.98
	(f) Others	9.18	11.80	8.03	35.39
	Total	22,642.98	19,035.96	20,790.21	80,149.34
	Less : Inter Segment Revenue	-	-	-	-
	Net Sales / Income from Operations	22,642.98	19,035.96	20,790.21	80,149.34
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]				
	(a) Animal Welfare	234.13	320.37	215.60	1,098.52
	(b) Consumer Products	125.71	285.43	603.77	2,345.32
	(c) Medical Devices	806.81	642.65	562.29	2,215.05
	(d) Protective Devices	(544.34)	631.76	(154.36)	252.62
	(e) Foods	294.11	132.96	108.59	449.89
	(f) Others	7.82	(9.90)	6.93	14.70
	Total	924.24	2,003.27	1,342.82	6,376.10
	Less : Finance Cost	76.96	90.47	85.79	332.42
	Less : Unallocable Expenses (Net of Unallocable Income)	(918.07)	(262.80)	(2,822.40)	(4,789.50)
	Total Profit (+) / Loss (-) before tax	1,765.35	2,175.60	4,079.43	10,833.18
		As on 30/06/2025	As on 31/03/2025	As on 30/06/2024	As on 31/03/2025
3.	Segment Assets:				
	(a) Animal Welfare Division	3,970.40	3,859.37	3,925.91	3,859.37
	(b) Consumer Products	5,033.32	4,521.96	4,187.30	4,521.96
	(c) Medical Devices	8,271.00	7,135.97	6,633.64	7,135.97
	(d) Protective Devices	13,851.90	13,715.76	13,390.58	13,715.76
	(e) Foods	6,738.07	6,931.64	6,734.84	6,931.64
	(f) Others	296.02	289.73	287.61	289.73
	Total	38,160.71	36,454.43	35,159.88	36,454.43
	Unallocated	92,925.86	91,664.24	90,356.01	91,664.24
	Total Assets	1,31,086.57	1,28,118.67	1,25,515.89	1,28,118.67



		As on 30/06/2025	As on 31/03/2025	As on 30/06/2024	As on 31/03/2025
4.	Segment Liabilities:				
(a)	Animal Welfare Division	2,769.03	2,920.65	3,336.85	2,920.65
(b)	Consumer Products	6,462.54	6,568.01	6,916.36	6,568.01
(c)	Medical Devices	1,819.50	1,367.74	1,482.68	1,367.74
(d)	Protective Devices	4,274.46	4,324.52	4,166.46	4,324.52
(e)	Foods	1,587.40	1,665.60	1,540.76	1,665.60
(f)	Others	136.43	136.92	149.91	136.92
	Total	17,049.36	16,983.44	17,593.02	16,983.44
	Unallocated	6,175.26	4,630.41	4,484.00	4,630.41
	Total Liabilities	23,224.62	21,613.85	22,077.02	21,613.85

Notes:

- Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
- Details of products included in each of the Segments are as below :
 - ❖ Animal Welfare comprise products for Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Griewater, EVA Range of Cosmetics, Good Home Range of Scrubbers, Air Fresheners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
- The segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

Place : Chennai
Date : August 04, 2025

T T RAGHUNATHAN
Executive Chairman



**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025


(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			
		(30/06/2025)	(31/03/2025)	(30/06/2024)	(31/03/2025)
		Unaudited	Audited	Unaudited	Audited
1.	Total income from Operations	22,642.98	19,035.96	20,790.21	80,149.34
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	1,765.35	2,761.99	2,102.38	9,442.52
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	1,765.35	2,175.60	4,079.43	10,833.18
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	1,299.94	1,614.83	3,157.51	8,165.69
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	1,357.13	1,052.27	3,346.98	7,825.96
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	1,04,650.36
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)				
	(a) Basic (in Rs.)	9.20	11.43	22.35	57.79
	(b) Diluted (in Rs.)	9.20	11.43	22.35	57.79

Notes:

- (1) The above is an extract of the detailed Statement of Unaudited Financial Results for the First Quarter ended June 30, 2025, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The above financial results for the First Quarter ended June 30, 2025 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 04, 2025 at the Registered Office of the Company, also with the provision of Video Conferencing facility.
- (3) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (4) (a) During the first quarter of the previous year, the Company had sold Leasehold land with building at Mahindra World City, Chennai for a consideration of Rs.2,300 lakhs and the profit on sale amounting to Rs.1,977.05 lakhs (Net) has been considered in the above results.
(b) During the fourth quarter of the previous year, the Company had written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers.
- (5) The figures for the Quarter ended March 31, 2025 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to Limited Review.
- (6) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (7) The full financial results for the First Quarter ended June 30, 2025 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED


T T RAGHUNATHAN
 Executive Chairman

 Place : Chennai
 Date : August 04, 2025

Independent Auditor's Review Report on review of Interim financial results**To the Board of Directors of TTK Healthcare Limited**

We have reviewed the accompanying Statement of Unaudited financial results ("the Statement") of TTK Healthcare Limited ("the Company") for the quarter and period ended 30th June 2025. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing obligations) which has been initialed by us for identification purposes.

Management's Responsibility

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

Attention is drawn to the fact that the figures for the quarter ended 31st March 2025 as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year which were subject to limited review by us.

Our conclusion is not modified in respect of this matter.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No. 003990S/S200018

P. Devi

Devi P

Partner

Membership No. 223137



Place: Chennai

Date: 04th August 2025

UDIN No. 25223137BM1NVV2941